Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 939

1.

[Atorvastatin therapy under clinical practice conditions - which LDL-C levels are achieved in patients at very high cardiovascular risk?]

Laufs U, Jannowitz C, Pittrow D.

Dtsch Med Wochenschr. 2017 Aug;142(16):1249-1252. doi: 10.1055/s-0042-121868. Epub 2017 Jul 27. German.

PMID:
28750422
2.

Statin use reduces cardiovascular events and all-cause mortality amongst Chinese patients with type 2 diabetes mellitus: a 5-year cohort study.

Fung CSC, Wan EYF, Chan AKC, Lam CLK.

BMC Cardiovasc Disord. 2017 Jun 24;17(1):166. doi: 10.1186/s12872-017-0599-x.

3.

Diabetic and Obese Patient Clinical Outcomes Improve During a Care Management Implementation in Primary Care.

Holtrop JS, Luo Z, Piatt G, Green LA, Chen Q, Piette J.

J Prim Care Community Health. 2017 Oct;8(4):312-318. doi: 10.1177/2150131917715536. Epub 2017 Jun 23.

PMID:
28645227
5.

[Pathogenetic substantiation of complex treatment of nonalcoholic steatohepatitis and steatosis in patients with pre-diabetes and type 2 diabetes].

Чопей ІВ, Івачевська ВВ, Чубірко КІ, Гряділь ТІ, Гечко ММ.

Wiad Lek. 2017;70(2):169-173. Ukrainian.

PMID:
28511152
6.

Can LDL cholesterol be too low? Possible risks of extremely low levels.

Olsson AG, Angelin B, Assmann G, Binder CJ, Björkhem I, Cedazo-Minguez A, Cohen J, von Eckardstein A, Farinaro E, Müller-Wieland D, Parhofer KG, Parini P, Rosenson RS, Starup-Linde J, Tikkanen MJ, Yvan-Charvet L.

J Intern Med. 2017 Jun;281(6):534-553. doi: 10.1111/joim.12614. Review.

PMID:
28295777
8.

Diabetes Secondary to Treatment with Statins.

Laakso M, Kuusisto J.

Curr Diab Rep. 2017 Feb;17(2):10. doi: 10.1007/s11892-017-0837-8. Review.

PMID:
28155189
9.

Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes.

Khavandi M, Duarte F, Ginsberg HN, Reyes-Soffer G.

Curr Cardiol Rep. 2017 Jan;19(1):7. doi: 10.1007/s11886-017-0818-1. Review.

10.

The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins.

Athyros VG, Tziomalos K, Doumas M, Sfikas G, Karagiannis A.

Curr Pharm Des. 2017;23(10):1477-1483. doi: 10.2174/1381612823666170125154257. Review.

PMID:
28128061
11.

Predictive value of non-fasting remnant cholesterol for short-term outcome of diabetics with new-onset stable coronary artery disease.

Hong LF, Yan XN, Lu ZH, Fan Y, Ye F, Wu Q, Luo SH, Yang B, Li JJ.

Lipids Health Dis. 2017 Jan 13;16(1):7. doi: 10.1186/s12944-017-0410-0.

12.

Stress hyperglycemia and acute ischemic stroke in-hospital outcome.

Tziomalos K, Dimitriou P, Bouziana SD, Spanou M, Kostaki S, Angelopoulou SM, Papadopoulou M, Giampatzis V, Savopoulos C, Hatzitolios AI.

Metabolism. 2017 Feb;67:99-105. doi: 10.1016/j.metabol.2016.11.011. Epub 2016 Nov 25.

PMID:
28081783
13.

Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with type 2 diabetes and diabetic retinopathy.

Chung YR, Park SW, Choi SY, Kim SW, Moon KY, Kim JH, Lee K.

Cardiovasc Diabetol. 2017 Jan 7;16(1):4. doi: 10.1186/s12933-016-0486-2.

14.

Invalidisierende Muskelschwäche.

Oestmann A, Bründler J, Repond F.

Praxis (Bern 1994). 2017 Jan;106(1):45-47. doi: 10.1024/1661-8157/a002576. Review. German. No abstract available.

PMID:
28055319
15.

Circulating MicroRNA-122 Is Associated With the Risk of New-Onset Metabolic Syndrome and Type 2 Diabetes.

Willeit P, Skroblin P, Moschen AR, Yin X, Kaudewitz D, Zampetaki A, Barwari T, Whitehead M, Ramírez CM, Goedeke L, Rotllan N, Bonora E, Hughes AD, Santer P, Fernández-Hernando C, Tilg H, Willeit J, Kiechl S, Mayr M.

Diabetes. 2017 Feb;66(2):347-357. doi: 10.2337/db16-0731. Epub 2016 Nov 29.

16.

Effect of Combination Cholesterol-Lowering Therapy and Triglyceride-Lowering Therapy on Medical Costs in Patients With Type 2 Diabetes Mellitus.

Nichols GA, Reynolds K, Olufade T, Kimes TM, O'Keeffe-Rosetti M, Sapp DS, Anzalone D, Fortmann SP.

Am J Cardiol. 2017 Feb 1;119(3):410-415. doi: 10.1016/j.amjcard.2016.10.029. Epub 2016 Nov 4.

PMID:
27890243
17.

Therapy with atorvastatin versus rosuvastatin reduces urinary podocytes, podocyte-associated molecules, and proximal tubule dysfunction biomarkers in patients with type 2 diabetes mellitus: a pilot study.

Vlad A, Vlad M, Petrica L, Ursoniu S, Gadalean F, Popescu R, Vlad D, Dumitrascu V, Gluhovschi G, Gluhovschi C, Velciov S, Bob F, Matusz P, Secara A, Simulescu A, Jianu DC.

Ren Fail. 2017 Nov;39(1):112-119. doi: 10.1080/0886022X.2016.1254657. Epub 2016 Nov 13.

PMID:
27841047
18.

Consensus on the Statin of Choice in Patients with Impaired Glucose Metabolism: Results of the DIANA Study.

Millán Núñez-Cortés J, Cases Amenós A, Ascaso Gimilio JF, Barrios Alonso V, Pascual Fuster V, Pedro-Botet Montoya JC, Pintó Sala X, Serrano Cumplido A.

Am J Cardiovasc Drugs. 2017 Apr;17(2):135-142. doi: 10.1007/s40256-016-0197-9.

19.

Lipoprotein(a) concentrations, apolipoprotein(a) isoforms and clinical endpoints in haemodialysis patients with type 2 diabetes mellitus: results from the 4D Study.

Kollerits B, Drechsler C, Krane V, Lamina C, März W, Dieplinger H, Ritz E, Wanner C, Kronenberg F; German Diabetes and Dialysis Study Investigators.

Nephrol Dial Transplant. 2016 Nov;31(11):1901-1908. Epub 2016 Jan 10.

PMID:
26754832
20.

Metabolic Markers to Predict Incident Diabetes Mellitus in Statin-Treated Patients (from the Treating to New Targets and the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trials).

Kohli P, Knowles JW, Sarraju A, Waters DD, Reaven G.

Am J Cardiol. 2016 Nov 1;118(9):1275-1281. doi: 10.1016/j.amjcard.2016.07.054. Epub 2016 Aug 12.

PMID:
27614854

Supplemental Content

Loading ...
Support Center